Balyasny Asset Management’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6,040,590
| Closed | -$436M | – | 3436 |
|
|
2025
Q4 | $436M | Buy |
+6,040,590
| New | +$390M | 0.55% | 23 |
|
|
2025
Q1 | – | Sell |
-137,057
| Closed | -$3.99M | – | 3214 |
|
|
2024
Q4 | $3.99M | Sell |
137,057
-23,752
| -15% | -$993K | 0.01% | 1380 |
|
|
2024
Q3 | $7.39M | Buy |
+160,809
| New | +$6.98M | 0.01% | 1088 |
|
|
2024
Q2 | – | Sell |
-51,055
| Closed | -$1.3M | – | 3023 |
|
|
2024
Q1 | $1.3M | Sell |
51,055
-1,164,782
| -96% | -$18.3M | ﹤0.01% | 1687 |
|
|
2023
Q4 | $11M | Sell |
1,215,837
-804,053
| -40% | -$5.37M | 0.02% | 828 |
|
|
2023
Q3 | $12.9M | Buy |
2,019,890
+27,056
| +1% | +$233K | 0.03% | 747 |
|
|
2023
Q2 | $22.1M | Buy |
1,992,834
+1,370,920
| +220% | +$17.2M | 0.05% | 489 |
|
|
2023
Q1 | $9.55M | Sell |
621,914
-26,912
| -4% | -$592K | 0.02% | 794 |
|
|
2022
Q4 | $14.4M | Buy |
648,826
+591,619
| +1,034% | +$8.82M | 0.04% | 600 |
|
|
2022
Q3 | $934K | Sell |
57,207
-129,495
| -69% | -$2.48M | ﹤0.01% | 1840 |
|
|
2022
Q2 | $2.71M | Buy |
+186,702
| New | +$2.78M | 0.01% | 1249 |
|
|
2021
Q3 | – | Sell |
-156,047
| Closed | -$3.86M | – | 2357 |
|
|
2021
Q2 | $3.86M | Buy |
+156,047
| New | +$3.63M | 0.02% | 804 |
|
Other funds holding RNAM
Balyasny Asset Management's RNAM Position: Q1 2026 in Review
Balyasny Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 6,040,590 shares — an estimated $436M sold.
Balyasny Asset Management first reported a position in RNAM in Q2 2021 and held it in 12 quarters. The position peaked at $436M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Balyasny Asset Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Balyasny Asset Management sold 6,040,590 Avidity Biosciences shares in Q1 2026, an estimated $436M.
- Balyasny Asset Management first reported a position in Avidity Biosciences in Q2 2021 and held it in 12 quarters.
- Balyasny Asset Management's Avidity Biosciences position peaked at $436M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.